What is our focus?
Making Good Drugs Great. To build a Biobetter company by taking select biological drugs or their biosimilars and developing long-acting versions of those products. Such novel versions of innovator drugs, whose performance has been enhanced by modifications...
Learn More01. Patient-centric
The drug delivery platform(s) is natural and biocompatible unlike other delivery systems that are synthetic and merely tolerated by the body. Such a platform(s) benefits patients with its non-toxic potential and its ability to increase the half-life of a drug, requiring less frequent administration.
Learn More02. Business-focused
DNX's pipeline co-development strategy is based on a combination of Internal Product Pipeline Development and Biopharmaceutical Corporate Partnering. The goal is to increase value along the development
chain by way of monetization of select target molecules.
DNX-114
Treatment of rheumatoid, juvenile rheumatoid and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis.
DNX-214
A monoclonal antibody fragment derived from the same parent mouse antibody as bevacizumab. An anti-angiogenic that has been approved for the treatment of age-related wet macular degeneration.
DNX-314
Development of the first, half-life extended version of this proven and safe commercially-approved product to target two new indications: osteoarthritis (OA) and type-2 diabetes. A 330-350 fold increase in half-life over the un-modified molecule has been demonstrated in preclinical data.
DNX-414
Treatment of metabolic diseases and diabetes. Preclinical data suggests that the half-life extended molecule has significantly enhanced pharmacological properties over the un-modified molecule in terms circulating half-life, potency levels and solubility.
DNX-514
A FAb fragment of a recombinant human IgG1 monoclonal antibody used as a TNF inhibiting anti-inflammatory drug for the treatment of RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.